Mario Sznol MD

Hematologic Oncology, Melanoma

Professor of Medicine (Medical Oncology); Co-Director, Yale SPORE in Skin Cancer

2111 Sole Mia WayNorth Miami, FL 33181
Phone+1 786-392-7653
Fax+1 786-392-5219

Dr. Sznol is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sznol's full profile Already have an account?

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1985 - 1987
Baylor College of MedicineResidency, Internal Medicine, 1982 - 1985
Baylor College of MedicineClass of 1982

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2026 - 2028
CT State Medical License 2000 - 2026
MD State Medical License 1987 - 2001
TX State Medical License 1983 - 1991
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
TERMINATED
PHASE1
3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors
COMPLETED
PHASE1
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy
COMPLETED
PHASE1

Publications & Presentations

PubMed

Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studies.
Coren Lahav, Nili Dahan, Michal Harel, Yehonatan Elon, Itamar Sela
Journal of Pharmaceutical and Biomedical Analysis. 2026-07-15
Non-invasive profiling of the tumour microenvironment with spatial ecotypes.
Wubing Zhang, Erin L Brown, Abul Usmani, Noah Earland, Minji Kang
Nature. 2026-06-01
Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes Leads to a Dominant Exhausted T-cell Population with a Lack of Memory Markers.
Gianfilippo Coppola, Samuel Kerr, Pei-Chun Cha, Alexey Bersenev, Kelly Olino
Cancer Immunology Research. 2026-05-04

Journal Articles

Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...
Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma
Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature

Lectures

Chair - Hematologic Malignancies and CAR-T Cell Therapy. Hematologic Malignancies and CAR-T Cell Therapy
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Case Presentations. Managing Immune-Related Adverse Events: The Challenge to Maximize the Risk/Benefit Ratio (A Case-Based Discussion)
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Chair - Basic Principles of Immunotherapy. Basic Principles of Immunotherapy
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Press Mentions

Immunotherapy: Balancing Cancer Treatment Benefits and RisksMay 2nd, 2025
Yale Study Highlights Unmet Needs for Patients with Melanoma Who Progress or Relapse After Immunotherapy TreatmentAugust 30th, 2024
Crisis in Oncology Research Demands Urgent Action, Stakeholders SayNovember 4th, 2022